Additional consideration contract with customer liability.

No definition available.

Name:	rptx_AdditionalConsiderationContractWithCustomerLiability
Namespace Prefix:	rptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amoun t of collaboration revenue receivable

+ References

No definition available.

+ Details

Name:	rptx_CollaborationRevenueReceivable
Namespace Prefix:	rptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaboration term expiration period.

+ References

No definition available.

+ Details

Name:	rptx_CollaborationTermExpirationPeriod
Namespace Prefix:	rptx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Estimated period of completion of trials to get revenue.

+ References

No definition available.

+ Details

Name:	rptx_EstimatedPeriodOfCompletionOfTrialsToGetRevenue
Namespace Prefix:	rptx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestones payments.

+ References

No definition available.

+ Details

Name:	rptx_MilestonesPayments
Namespace Prefix:	rptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.

+ References

+ Details

Name:	us-gaap_DeferredRevenueNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously reported as deferred or unearned revenue.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	dei_LegalEntityAxis=rptx_BristolMyersSquibbCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rptx_CollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_ProductResearchActivityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_ResearchDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rptx_HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_CombinedLicensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_ClinicalTrialMaterialsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_AdditionalClinicalDevelopmentPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rptx_UpfrontNonRefundableFirstPaymentReceivedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreement - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended
	Jul. 31, 2022	Jun. 30, 2020	May 30, 2020	Mar. 31, 2023	Mar. 31, 2022	Feb. 28, 2023	Dec. 31, 2022	May 31, 2020
Bristol-Myers Squibb Company
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received				$ 50,000
Bristol-Myers Squibb Company \| Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration term expiration period			42 months
Initial nonrefundable upfront fee received		$ 50,000
Non-refundable payment received								$ 50,000
Deferred revenue, current				27,000			$ 27,400
Bristol-Myers Squibb Company \| Collaboration and License Agreement \| Product Research Activity [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue recognized				400
Bristol-Myers Squibb Company \| Collaboration and License Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received								301,000
Bristol-Myers Squibb Company \| Collaboration and License Agreement \| Maximum \| Research, Development and Regulatory Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received								176,000
Bristol-Myers Squibb Company \| Collaboration and License Agreement \| Maximum \| Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments entitled to be received								$ 125,000
Roche
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received				138,626
Roche \| Combined licenses
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received				105,327
Roche \| Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Estimated period of completion of trials to get revenue	24 months
Non-refundable payment received				134,600
Deferred revenue recognized				5,300	$ 0
Deferred revenue				16,700			18,000
Deferred revenue, current				15,400			15,300
Deferred revenue, noncurrent				1,300			$ 2,700
Roche \| Collaboration and License Agreement \| Commercial Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones payments				1,172,000
Roche \| Collaboration and License Agreement \| Clinical trial materials
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received				5,600
Roche \| Collaboration and License Agreement \| Product additional clinical development plan
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue receivable						$ 4,000
Non-refundable payment received				4,000
Amount of additional consideration						$ 4,000
Roche \| Collaboration and License Agreement \| Upfront non refundable first payment received
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable payment received				$ 125,000